期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Effect of Two Kinds of Different Combined Oral Contraceptives Used on Bone Mineral Density in Women of Reproductive Age 被引量:3
1
作者 Rui-jian LIU Ling GAI +2 位作者 Yi-fang JIA Ping GAI Xiao-jie YU 《Journal of Reproduction and Contraception》 CAS 2011年第3期145-151,共7页
Objective To compare bone mineral density (BMD) among users of ethinylestradiol/ desogestrel, ethinylestradiol/cyproterone acetate and nonhormonal control subjects. Methods The study included 154 women aged 25-40 ye... Objective To compare bone mineral density (BMD) among users of ethinylestradiol/ desogestrel, ethinylestradiol/cyproterone acetate and nonhormonal control subjects. Methods The study included 154 women aged 25-40 years. Forty-six women were using ethinylestradiol/desogestrel (group A) and 55 women using ethinylestradiol/cyproterone acetate (group B)for 24 months and 53 women using nonhormonal contraception as control subjects (group C). BMD of the lumbar spine and femoral neck were obtained using dual energy X-ray absorptiometry, comparing mean BMD changes in combined oral contraceptives (COCs) users with nonusers. Results For 24 months of treatment, lumbar spine and femoral neck BMD values in women who used ethinylestradiol/desogestrel and ethinylestradiol/cyproterone acetate were not significantly different compared with the baseline and the values of subjects in nonuser (P〉0.05). Conclusion There was no statistical difference in BMD between the users of ethinylestradiol/desogestrel or ethinylestradiol/cyproterone acetate and nonusers. 展开更多
关键词 combined oral contraceptives (COC) ethinylestradiol/desogestrel ethinylestradiol/ cyproterone acetate bone mineral density (BMD)
原文传递
Effect of Combined Oral Contraceptive Use on Bone Mineral Density in Adolescent Females 被引量:2
2
作者 Ling GAI Xia LIU +3 位作者 Ping GAI Ai-dong ZHANG Ping JIANG Wei ZHANG 《Journal of Reproduction and Contraception》 CAS 2012年第3期179-185,共7页
Objective To compare adolescents' bone mineral density (BMD) between users of combined oral contraceptive (Marvelon, desogestrel/ethinylestradiol) and no.nhormonal control subjects. Methods The study included 127... Objective To compare adolescents' bone mineral density (BMD) between users of combined oral contraceptive (Marvelon, desogestrel/ethinylestradiol) and no.nhormonal control subjects. Methods The study included 127 women who aged between 16 and 18 years using Marvelon for 24 months and 115 women who aged between 16 and 18 years using nonhormonal contraception as control subjects. BMD of the lumbar spine and femoral neck were obtained using dual energy X-ray absorptiometry. Results After 24 months of Marvelon use, as compared with baseline, the mean BMD in lumbar spine and femoral neck were decreased by 0.30% and 0.61%, respectively. While in the nonusers group, the mean BMD were increased by 1.88% and 1.10%, respectively. Lumbar spine and femoral neck BMD in women who used Marvelon were not significantly different compared with the subjects who used nonhormonal contra- ception (P〉0. 05). Conclusion Two years of Marvelon use had no significant effect on BMD, but it remains unknown whether longer than 2 years of use has a significant adverse effect on the attainment of peak bone mass. 展开更多
关键词 combined oral contraceptive Marvelon (desogestrel/ethinylestradiol) bonemineral density (BMD) CONTRACEPTION
原文传递
Post-marketing Surveillance for Combined Oral Contraceptive Containing Desogestrel(Marvelon~) in Chinese Rural Areas 被引量:1
3
作者 Hong-yan TANG Ying LI +8 位作者 Yu-lin WU Jian ZHOU Lei BA Xiao-ping GU Wei-dong WANG Hui YAO Nai-xiu REN Jian-hong CHEN Lian-fang XU 《Journal of Reproduction and Contraception》 CAS 2008年第4期193-200,共8页
To assess the side effects and the continuation rate of combined oral contraceptive (COC) containing desogestrel (Marvelon) during 12 months. Methods This was a post-marketing surveillance study on Marvelon COC am... To assess the side effects and the continuation rate of combined oral contraceptive (COC) containing desogestrel (Marvelon) during 12 months. Methods This was a post-marketing surveillance study on Marvelon COC among 870 healthy rural women in 5 different counties of Jiangsu Province during 12 months. Results About 24.02% of the women who used Marvelon COC experienced side effects during 12 months. Gastrointestinal disorder, bleeding/spotting and chloasma were ranked the first three in the side effects. The rate of side effects of Marvelon COC users during the first 3 months in southern area of Jiangsu was significantly higher than that of users in northern area of Jiangsu. Most of the users did not experience obvious weight changes i.e., loss or increase in weight of more than 5 kg during 12 months. Blood pressure and biochemical indicators of almost 99% among users were within the normal range. The gross cumulative continuation rate for 12 months was 83.14%; the most common medical reason for discontinuation was gastrointestinal disorder. There was an increased risk of discontinuation use among women with lower educational level. Conclusion Marvelon COC brought fewer side effects and was well accepted when applied in Chinese rural women. 展开更多
关键词 combined oral contraceptive DESOGESTREL side effects continuation rate
原文传递
Comparison of Risks of Thromboembolism of Drospirenone-Containing and Nondrospirenone -Containing Combined Oral Contraceptive Use: A Meta-Analysis
4
作者 Wan-Lin Zhang Zhe Dong +4 位作者 Jun-Yan Zhang Min-Zhi Lyu Wei Zhang Jian-Lei Huang Xin Yang 《Reproductive and Developmental Medicine》 CSCD 2021年第3期154-160,共7页
This study aimed to estimate the risk of venous thromboembolism(VTE),arterial thromboembolism(ATE),and other side effects following the use of drospirenone(DRSP)-containing combined oral contraceptives(COCs).When comp... This study aimed to estimate the risk of venous thromboembolism(VTE),arterial thromboembolism(ATE),and other side effects following the use of drospirenone(DRSP)-containing combined oral contraceptives(COCs).When compared with non-DRSP-containing COCs,DRSP-containing COCs decreased the risk of VTE by 15%in the overall study population,although this was not statistically significant(adjusted hazard ratio/risk ratio[95%confidence interval]0.85[0.69,1.04]).DRSP-containing COCs also showed significant benefits in terms of ATE risk.The body mass index of the subjects significantly decreased by 0.64 kg/m^(2) after taking the DRSP-containing COCs for 6 months.We concluded that DRSP-containing COCs were safe for use and could be broadly recommended. 展开更多
关键词 Arterial Thromboembolism combined oral contraceptives DROSPIRENONE Venous Thromboembolism
原文传递
Comparison of Drospirenone-with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial 被引量:13
5
作者 Qiu-Yi Wang Yong Song +3 位作者 Wei Huang Li Xiao Qiu-Shi Wang Gui-Mei Feng 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第8期883-890,共8页
Background:While combined oral contraceptives (COCs) are commonly used to treat polycystic ovary syndrome (PCOS),comparative data regarding metabolic effects of different progestogens on this patient population a... Background:While combined oral contraceptives (COCs) are commonly used to treat polycystic ovary syndrome (PCOS),comparative data regarding metabolic effects of different progestogens on this patient population are missing.This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs,combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders.Methods:Ninety-nine women with PCOS and a metabolic disorder between January 2011 and January 2013 were enrolled into this prospective randomized clinical trial.Participants were randomized into two groups such as DRP-containing COCs,and CPA-containing COCs.Participants took COCs cyclically for 6 months,combined with metformin administration (1.5 g/d) and lifestyle modifications (diet and exercise).Clinical measures and biochemical and hormone profiles were compared.Comparisons for continuous variables were evaluated with paired and unpaired Student&#39;s t-tests.The Wilcoxon signed rank test was used when the data were not normally distributed.Analysis of covariance was used to control for age,body mass index (BMI),and baseline data of each analyzed parameter when compared between the two groups.Results:A total of 68 patients have completed the study.The combination regimen of COCs,metformin,and lifestyle modifications in these patients resulted in a significant decrease in BMI,acne,and hirsutism scores when compared to baseline levels in both groups (P 〈 0.05).Blood pressure (BP) was significantly different in the CPA group when compared to baseline (75.14 ± 6.77 mmHg vs.80.70 ± 5.60 mmHg,P 〈 0.01),and after 6 months of treatment,only the change in systolic BP was significantly different between the two groups (4.00 [-6.00,13.00] mmHg vs.-3.50 [-13.00,9.00] mmHg,P =0.009).Fasting glucose,fasting insulin,and homeostasis model assessment-insulin resistance decreased significantly in the DRP group (5.40 ± 0.41 mmol/L vs.5.21 ± 0.32 mmol/L,P =0.041;13.90 [10.50,18.40] μU/ml vs.10.75 [8.60,13.50] μU/ml,P =0.020;3.74 [2.85,4.23] vs.2.55 [1.92,3.40],P =0.008) but did not differ between the two groups.While individual lipid profiles increased in both groups,no statistically significant difference was observed.Conclusions:DRP-containing COCs combined with metformin and lifestyle modifications could better control BP and correct carbohydrate metabolism in women with PCOS and metabolic disorders compared with CPA-containing COCs. 展开更多
关键词 Cyproterone Acetate DROSPIRENONE Metabolic Disorder oral contraceptives combined Polycystic Ovary Syndrome
原文传递
Medical treatments of endometriosis: a review
6
作者 Bahi Elbasueny Maya Geets +3 位作者 Emily C.Yang Catherine Allaire Paul J.Yong Mohamed A.Bedaiwy 《Reproductive and Developmental Medicine》 CAS CSCD 2023年第3期166-179,共14页
Endometriosis is a chronic gynecological disorder that affects approximately 10%of women of reproductive age.Most medical treatments used today for endometriosis pain are hormonal therapies,which are not an option for... Endometriosis is a chronic gynecological disorder that affects approximately 10%of women of reproductive age.Most medical treatments used today for endometriosis pain are hormonal therapies,which are not an option for those trying to conceive and are not tolerated by a subset of patients due to side effects.In this article,we offer a comprehensive review of current and investigational medical therapeutic options used to treat endometriosis pain,as well as a symptom-based systematic approach for patients with painful endometriosis.We have also included recommendations for research to enhance the evolution of novel therapeutic options.A thorough literature search was carried out,and the data were synthesized using a synthesis matrix that classifies and categorizes various arguments. 展开更多
关键词 ENDOMETRIOSIS Pelvic pain Medical treatment Medical therapy Non-steroidal anti-inflammatory drugs combined oral contraceptives PROGESTERONE GnRH agonist GnRH antagonist Aromatase inhibitors Investigational endometriosis treatments
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部